Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has provided an announcement.
On February 12, 2026, OKYO Pharma announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, expected to raise about $20 million in gross proceeds. The company also granted the underwriter a 30-day option to buy up to 1,622,250 additional shares, which would lift gross proceeds to roughly $23 million before expenses if fully exercised.
OKYO plans to deploy the net proceeds to advance clinical development of its pipeline, including its lead candidate for neuropathic corneal pain, as well as for general corporate purposes and working capital. The deal, managed solely by Piper Sandler and expected to close around February 17, 2026, strengthens the company’s funding base as it prepares for a pivotal Phase 2b/3 trial, potentially enhancing its position in the niche ocular pain and inflammatory eye disease market.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market, focused on developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. Its flagship drug candidate, urcosimod, recently completed a successful Phase 2 trial in neuropathic corneal pain, with a roughly 150-patient Phase 2b/3 multiple-dose study planned for the first half of this year.
Average Trading Volume: 207,224
Technical Sentiment Signal: Sell
Current Market Cap: $73.34M
For an in-depth examination of OKYO stock, go to TipRanks’ Overview page.